Registry of Lobbyists

Advanced Registry Search Results

Search Criteria

Search for novartis pharmaceuticals canada in registrations and monthly communication reports

If you would like to view a summary of the last 12 months for a lobbying activity, use the 12-Month Lobbying Activity Search

Registration (101)
Results: 1-50 | Export
  1. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Mark Vineis, Country President
    Registration: 37 of 37 (2024-01-01 to present)
    Posted: 2024-02-07
    Subject matter details: 9
    Government institutions: 14
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  2. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Pedro Ferreira, Country President
    Registration: 36 of 37 (2023-11-01 to 2024-01-01)
    Posted: 2023-12-07
    Subject matter details: 9
    Government institutions: 14
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 1
  3. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Pedro Ferreira, Country President
    Registration: 35 of 37 (2023-10-01 to 2023-11-01)
    Posted: 2023-10-16
    Subject matter details: 9
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 1
  4. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Andrea Marazzi, Country President
    Registration: 34 of 37 (2023-01-13 to 2023-10-01)
    Posted: 2023-01-13
    Subject matter details: 9
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 1
  5. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Andrea Marazzi, Country President
    Registration: 33 of 37 (2022-10-05 to 2023-01-13)
    Posted: 2022-10-05
    Subject matter details: 11
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  6. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Andrea Marazzi, Country President
    Registration: 32 of 37 (2022-06-01 to 2022-10-05)
    Posted: 2022-06-16
    Subject matter details: 11
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  7. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Christian Macher, Country President & Oncology General Manager Canada
    Registration: 31 of 37 (2021-12-16 to 2022-06-01)
    Posted: 2021-12-16
    Subject matter details: 11
    Government institutions: 13
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 3
  8. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Christian Macher, Country President & Oncology General Manager Canada
    Registration: 30 of 37 (2021-05-03 to 2021-12-16)
    Posted: 2021-05-03
    Subject matter details: 11
    Government institutions: 12
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 3
  9. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Christian Macher, Country President & Oncology General Manager Canada
    Registration: 29 of 37 (2020-09-14 to 2021-05-03)
    Posted: 2020-09-14
    Subject matter details: 11
    Government institutions: 11
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 3
  10. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Christian Macher, Country President & Oncology General Manager Canada
    Registration: 28 of 37 (2020-06-04 to 2020-09-14)
    Posted: 2020-06-05
    Subject matter details: 11
    Government institutions: 10
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 3
  11. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Christian Macher, Country President & Oncology General Manager Canada
    Registration: 27 of 37 (2020-02-14 to 2020-06-04)
    Posted: 2020-02-14
    Subject matter details: 11
    Government institutions: 10
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  12. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Christian Macher, Country President & Oncology General Manager Canada
    Registration: 26 of 37 (2019-11-29 to 2020-02-14)
    Posted: 2019-11-29
    Subject matter details: 11
    Government institutions: 9
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  13. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Christian Macher, Country President & Oncology General Manager Canada
    Registration: 25 of 37 (2019-05-01 to 2019-11-29)
    Posted: 2019-06-20
    Subject matter details: 11
    Government institutions: 9
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  14. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Thea Discepola, Interim President
    Registration: 24 of 37 (2019-03-01 to 2019-05-01)
    Posted: 2019-04-12
    Subject matter details: 11
    Government institutions: 9
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  15. Sandoz Canada Inc.
    Type: Consultant
    Lobbyist: Julian Worsley, Miller Thomson LLP
    Registration: 1 of 1 (2018-11-09 to 2020-04-03)
    Posted: 2018-11-28
    Subject matter details: 1
    Government institutions: 2
    Communication techniques: 2
    Government funding: No
  16. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Janice Murray, President
    Registration: 23 of 37 (2018-06-11 to 2019-03-01)
    Posted: 2018-06-12
    Subject matter details: 11
    Government institutions: 8
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  17. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Janice Murray, President
    Registration: 22 of 37 (2018-05-14 to 2018-06-11)
    Posted: 2018-05-17
    Subject matter details: 11
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  18. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Janice Murray, President
    Registration: 21 of 37 (2018-03-20 to 2018-05-14)
    Posted: 2018-03-21
    Subject matter details: 13
    Government institutions: 6
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  19. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Janice Murray, President
    Registration: 20 of 37 (2017-10-18 to 2018-03-20)
    Posted: 2017-10-19
    Subject matter details: 12
    Government institutions: 6
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  20. Novartis Pharmaceutical Canada Inc
    Type: Consultant
    Lobbyist: Elaine Larsen Wells, Capital Hill Group
    Registration: 1 of 1 (2017-08-10 to 2018-07-17)
    Posted: 2017-08-11
    Subject matter details: 1
    Government institutions: 12
    Communication techniques: 2
    Government funding: No
  21. Novartis Pharmaceutical Canada Inc
    Type: Consultant
    Lobbyist: DAVID ANGUS, The Capital Hill Group Inc.
    Registration: 1 of 1 (2017-08-09 to 2018-12-06)
    Posted: 2017-08-10
    Subject matter details: 1
    Government institutions: 12
    Communication techniques: 2
    Government funding: No
  22. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Janice Murray, President
    Registration: 19 of 37 (2017-05-01 to 2017-10-18)
    Posted: 2017-05-30
    Subject matter details: 12
    Government institutions: 6
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  23. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Timothy Maloney, President
    Registration: 18 of 37 (2017-03-21 to 2017-05-01)
    Posted: 2017-03-21
    Subject matter details: 11
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  24. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Timothy Maloney, President
    Registration: 17 of 37 (2016-10-19 to 2017-03-21)
    Posted: 2016-10-21
    Subject matter details: 11
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  25. Novartis Pharmaceuticals Canada Inc.
    Type: Consultant
    Lobbyist: CARL BALTARE, GLOBAL PUBLIC AFFAIRS
    Registration: 12 of 12 (2016-07-15 to 2020-01-14)
    Posted: 2016-07-21
    Subject matter details: 8
    Government institutions: 5
    Communication techniques: 2
    Government funding: No
  26. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Timothy Maloney, President
    Registration: 16 of 37 (2016-05-27 to 2016-10-19)
    Posted: 2016-05-27
    Subject matter details: 11
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  27. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Timothy Maloney, President
    Registration: 15 of 37 (2016-01-12 to 2016-05-27)
    Posted: 2016-01-13
    Subject matter details: 10
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  28. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Timothy Maloney, President
    Registration: 14 of 37 (2015-08-18 to 2016-01-12)
    Posted: 2015-08-18
    Subject matter details: 12
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  29. Novartis Pharmaceuticals Canada Inc.
    Type: Consultant
    Lobbyist: CARL BALTARE, GLOBAL PUBLIC AFFAIRS
    Registration: 11 of 12 (2015-04-30 to 2016-07-15)
    Posted: 2015-05-01
    Subject matter details: 8
    Government institutions: 5
    Communication techniques: 2
    Government funding: No
  30. Novartis Pharmaceuticals Canada Inc.
    Type: Consultant
    Lobbyist: Ann Marie Pullen, Global Public Affairs
    Registration: 4 of 4 (2015-04-30 to 2016-02-24)
    Posted: 2015-05-01
    Subject matter details: 8
    Government institutions: 5
    Communication techniques: 2
    Government funding: No
  31. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Timothy Maloney, President
    Registration: 13 of 37 (2015-04-09 to 2015-08-18)
    Posted: 2015-04-09
    Subject matter details: 11
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  32. Novartis Pharmaceuticals Canada Inc.
    Type: Consultant
    Lobbyist: Jeff Rutledge, Hill+Knowlton Strategies
    Registration: 1 of 1 (2015-02-20 to 2015-07-23)
    Posted: 2015-02-24
    Subject matter details: 1
    Government institutions: 4
    Communication techniques: 3
    Government funding: No
  33. Novartis Pharmaceuticals Canada Inc.
    Type: Consultant
    Lobbyist: Angela Cerovic, HILL+KNOWLTON STRATEGIES
    Registration: 1 of 1 (2015-02-16 to 2015-10-16)
    Posted: 2015-02-19
    Subject matter details: 1
    Government institutions: 3
    Communication techniques: 3
    Government funding: No
  34. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Timothy Maloney, President
    Registration: 12 of 37 (2014-11-17 to 2015-04-09)
    Posted: 2014-11-19
    Subject matter details: 10
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  35. Novartis Pharmaceuticals Canada Inc.
    Type: Consultant
    Lobbyist: Ann Marie Pullen, Global Public Affairs
    Registration: 3 of 4 (2014-07-16 to 2015-04-30)
    Posted: 2014-07-16
    Subject matter details: 15
    Government institutions: 2
    Communication techniques: 3
    Government funding: No
  36. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Timothy Maloney, President
    Registration: 11 of 37 (2014-04-01 to 2014-11-17)
    Posted: 2014-07-07
    Subject matter details: 10
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  37. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Riad Sherif, President
    Registration: 10 of 37 (2014-02-21 to 2014-04-01)
    Posted: 2014-02-24
    Subject matter details: 10
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 3
  38. Novartis Pharmaceuticals Canada Inc.
    Type: Consultant
    Lobbyist: Ann Marie Pullen, Global Public Affairs
    Registration: 2 of 4 (2013-12-02 to 2014-07-16)
    Posted: 2013-12-12
    Subject matter details: 15
    Government institutions: 2
    Communication techniques: 3
    Government funding: No
  39. Novartis Pharmaceuticals Canada Inc.
    Type: Consultant
    Lobbyist: CARL BALTARE, GLOBAL PUBLIC AFFAIRS
    Registration: 10 of 12 (2013-12-02 to 2015-04-30)
    Posted: 2013-12-12
    Subject matter details: 15
    Government institutions: 11
    Communication techniques: 2
    Government funding: No
  40. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Riad Sherif, President
    Registration: 9 of 37 (2013-10-03 to 2014-02-21)
    Posted: 2013-10-03
    Subject matter details: 9
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 3
  41. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Riad Sherif, President
    Registration: 8 of 37 (2013-08-15 to 2013-10-03)
    Posted: 2013-08-15
    Subject matter details: 9
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 3
  42. Novartis Pharmaceuticals Canada Inc.
    Type: Consultant
    Lobbyist: CARL BALTARE, GLOBAL PUBLIC AFFAIRS
    Registration: 9 of 12 (2013-08-01 to 2013-12-02)
    Posted: 2013-08-02
    Subject matter details: 15
    Government institutions: 11
    Communication techniques: 2
    Government funding: No
  43. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Riad Sherif, President
    Registration: 7 of 37 (2013-03-04 to 2013-08-15)
    Posted: 2013-03-04
    Subject matter details: 9
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 3
  44. Novartis Pharmaceuticals Canada, Inc.
    Type: Consultant
    Lobbyist: Stephen Sampson, Global Public Affairs
    Registration: 2 of 2 (2013-01-15 to 2013-12-02)
    Posted: 2013-01-15
    Subject matter details: 14
    Government institutions: 10
    Communication techniques: 2
    Government funding: No
  45. Novartis Pharmaceuticals Canada, Inc.
    Type: Consultant
    Lobbyist: Roberta Kramchynsky, Global Public Affairs
    Registration: 6 of 6 (2013-01-15 to 2013-12-02)
    Posted: 2013-01-15
    Subject matter details: 14
    Government institutions: 11
    Communication techniques: 2
    Government funding: No
  46. Novartis Pharmaceuticals Canada Inc.
    Type: Consultant
    Lobbyist: Michael McCarthy, GrossoMcCarthy Inc.
    Registration: 1 of 1 (2012-11-21 to 2013-05-02)
    Posted: 2012-11-22
    Subject matter details: 1
    Government institutions: 1
    Communication techniques: 2
    Government funding: No
  47. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Riad Sherif, President
    Registration: 6 of 37 (2012-09-20 to 2013-03-02)
    Posted: 2012-09-21
    Subject matter details: 9
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  48. Novartis Pharmaceuticals Canada, Inc.
    Type: Consultant
    Lobbyist: Roberta Kramchynsky, Global Public Affairs
    Registration: 5 of 6 (2012-04-18 to 2013-01-15)
    Posted: 2012-04-18
    Subject matter details: 14
    Government institutions: 10
    Communication techniques: 2
    Government funding: No
  49. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Responsible officer: Riad Sherif, President
    Registration: 5 of 37 (2012-04-12 to 2012-09-20)
    Posted: 2012-04-13
    Subject matter details: 9
    Government institutions: 7
    Communication techniques: 2
    Government funding: No
    Employees who lobby: 2
  50. Novartis Pharmaceuticals Canada, Inc.
    Type: Consultant
    Lobbyist: Stephen Sampson, Global Public Affairs
    Registration: 1 of 2 (2012-01-03 to 2013-01-15)
    Posted: 2012-01-03
    Subject matter details: 14
    Government institutions: 9
    Communication techniques: 2
    Government funding: No

Monthly communication reports (84)
Results: 1-50 | Export
  1. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2024-02-29
    Posted: 2024-03-15
    Designated public office holders:
    • Rachel Blaney, Member of Parliament North Island Powell River | House of Commons
    Subject matters:
    • Health
    • Research and Development
  2. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2024-02-29
    Posted: 2024-03-15
    Designated public office holders:
    • Tom Kmiec, Member of Parliament, Calgary Shephard | House of Commons
    Subject matters:
    • Industry
    • Health
    • Science and Technology
  3. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2024-02-29
    Posted: 2024-03-15
    Designated public office holders:
    • Francesco Sorbara, Member of Parliment | House of Commons
    Subject matters:
    • Health
    • Industry
    • Research and Development
  4. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-12-07
    Posted: 2024-01-11
    Designated public office holders:
    • Ritu Banerjee, Assistant Deputy Minister, Director General's Office | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Health
    • Science and Technology
    • Industry
  5. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-11-08
    Posted: 2023-12-15
    Designated public office holders:
    • Ritu Banerjee, Assistant Deputy Minister, Director General's Office | Innovation, Science and Economic Development Canada (ISED)
    • Simon Kennedy, Sous-ministre | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Science and Technology
    • Industry
    • Health
  6. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-11-07
    Posted: 2023-12-15
    Designated public office holders:
    • Jessica La Forge, Policy Advisor | Pacific Economic Development Canada (PacifiCan)
    • Gurjiven Sandhu, Director of Policy | Pacific Economic Development Canada (PacifiCan)
    Subject matters:
    • Science and Technology
    • Health
  7. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-11-06
    Posted: 2023-12-15
    Designated public office holders:
    • Francesco Sorbara, Member of Parliment | House of Commons
    Subject matters:
    • Health
    • Industry
  8. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-11-06
    Posted: 2023-12-15
    Designated public office holders:
    • Chandra Arya, Member of Parliament | House of Commons
    Subject matters:
    • Health
  9. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-11-06
    Posted: 2023-12-15
    Designated public office holders:
    • Stephen Ellis, Member of Parliament | House of Commons
    Subject matters:
    • Health
  10. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-09-20
    Posted: 2023-10-16
    Designated public office holders:
    • Darryl Patterson, Director General | Innovation, Science and Economic Development Canada (ISED)
    • Christopher Johnstone, Assistant Deputy minister | Health Canada (HC)
    • Simon Kennedy, Sous-ministre | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Science and Technology
    • Health
    • Industry
    • Research and Development
  11. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-08-17
    Posted: 2023-09-15
    Designated public office holders:
    • Mark Holland, Minister of Health | Health Canada (HC)
    Subject matters:
    • Science and Technology
    • Health
  12. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-06-23
    Posted: 2023-06-28
    Designated public office holders:
    • Jocelyne Voisin, Assistant Deputy Minister | Health Canada (HC)
    Subject matters:
    • Health
    • Science and Technology
    • Research and Development
  13. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-06-22
    Posted: 2023-07-15
    Designated public office holders:
    • Jean-Sébastien Bock, Director of Policy, Minister's Office | Health Canada (HC)
    • Jean-Yves Duclos, Minister of Health | Health Canada (HC)
    • Sandenga Yeba, Senior Policy Advisor, Minister's Office | Health Canada (HC)
    Subject matters:
    • Industry
    • Research and Development
    • Science and Technology
    • Health
  14. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-06-06
    Posted: 2023-07-15
    Designated public office holders:
    • Andy Fillmore, Member of Parliament | House of Commons
    Subject matters:
    • Health
    • Science and Technology
    • Industry
  15. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-04-25
    Posted: 2023-05-15
    Designated public office holders:
    • Jocelyne Voisin, Assistant Deputy Minister | Health Canada (HC)
    Subject matters:
    • Science and Technology
    • Health
    • Industry
  16. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-04-25
    Posted: 2023-05-15
    Designated public office holders:
    • Bianca Hossain, Policy advisor, Minister's Office | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Industry
    • Research and Development
    • Health
    • Science and Technology
  17. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-04-24
    Posted: 2023-05-15
    Designated public office holders:
    • Dr. Stephen Ellis, Member of Parliament | House of Commons
    Subject matters:
    • Industry
    • Research and Development
    • Science and Technology
    • Health
  18. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-04-05
    Posted: 2023-05-15
    Designated public office holders:
    • Andy Fillmore, Member of Parliament | House of Commons
    Subject matters:
    • Science and Technology
    • Industry
    • Research and Development
    • Health
  19. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-03-10
    Posted: 2023-04-15
    Designated public office holders:
    • Jaxson Khan, Policy Advisor, Minister's Office | Innovation, Science and Economic Development Canada (ISED)
    • Pierre-Yves Bourque, Director of Operations, Ministers Office | Innovation, Science and Economic Development Canada (ISED)
    • Bianca Hossain, Policy advisor, Minister's Office | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Science and Technology
    • Health
  20. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-01-10
    Posted: 2023-02-15
    Designated public office holders:
    • Chris Zou, Policy Advisor, Office of Minister International Trade | Global Affairs Canada (GAC)
    Subject matters:
    • Health
    • Science and Technology
  21. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2023-01-04
    Posted: 2023-02-15
    Designated public office holders:
    • Dr. Stephen Ellis, Member of Parliament | House of Commons
    Subject matters:
    • Health
    • Research and Development
  22. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-11-23
    Posted: 2022-12-15
    Designated public office holders:
    • Ashley Wright, Chief of Staff to the Minister, Minister's Office | Pacific Economic Development Canada (PacifiCan)
    • Chris Zou, Policy Advisor, Office of the Minister of International Trade, Export Promotion, Small Business and Economic Development | Global Affairs Canada (GAC)
    • Zachary Nixon, Chief of Staff to the Minister, Minister's Office International Trade | Global Affairs Canada (GAC)
    • Alexandre Boulé, Director Regional Affairs, Minister's Office | Canadian Heritage (PCH)
    • Camille Benoit-Blouin, Special Assistant, Policy, Minister's Office International Trade, Export Promotion, Small Business and Economic Development | Global Affairs Canada (GAC)
    • Jessie Pierre, Director of Policy, Ministers office | Federal Economic Development Agency for Southern Ontario (FedDev)
    Subject matters:
    • Health
    • Industry
    • Research and Development
    • Science and Technology
  23. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-09-29
    Posted: 2022-10-15
    Designated public office holders:
    • Jean-Yves Duclos, Minister of Health | Health Canada (HC)
    Subject matters:
    • Health
    • Industry
  24. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-07-21
    Posted: 2022-08-15
    Designated public office holders:
    • Seamus O'Regan, Minister of Labour | Employment and Social Development Canada (ESDC)
    Subject matters:
    • Health
    • Industry
  25. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-06-28
    Posted: 2022-07-04
    Designated public office holders:
    • Simon Kennedy, Sous-ministre | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Industry
    • Health
    • International Trade
    • Science and Technology
    • Intellectual Property
  26. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-06-17
    Posted: 2022-07-04
    Designated public office holders:
    • Nancy Hamzawi, Assistant Deputy Minister | Health Canada (HC)
    • Stephen Lucas, Sous-ministre, Health Products and food branch | Health Canada (HC)
    Subject matters:
    • International Trade
    • Science and Technology
    • Health
    • Industry
    • Intellectual Property
  27. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-05-31
    Posted: 2022-06-05
    Designated public office holders:
    • Dr. Stephen Ellis, Member of Parliament | House of Commons
    Subject matters:
    • Health
  28. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-05-31
    Posted: 2022-06-05
    Designated public office holders:
    • Adam Van Koeverden, Member of Parliament | House of Commons
    Subject matters:
    • Health
  29. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-05-31
    Posted: 2022-06-05
    Designated public office holders:
    • Luc Berthold, Député | House of Commons
    • Richard Lehoux, Member of Parliament | House of Commons
    • Richard Martel, Member of Parliament | House of Commons
    • Bernard Genereux, Member of Parliament | House of Commons
    • Jacques Gourde, Member of Parliament | House of Commons
    Subject matters:
    • Industry
    • Health
  30. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-05-31
    Posted: 2022-06-05
    Designated public office holders:
    • Alexandre Boulerice, Member of Parliament | House of Commons
    Subject matters:
    • Health
    • Industry
  31. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-05-31
    Posted: 2022-06-05
    Designated public office holders:
    • Karl Sasseville, Deputy Chief of Staff, Minister's Office | Health Canada (HC)
    • Sandenga Yeba, Senior Policy Advisor, Minister's Office | Health Canada (HC)
    • Jamie Kippen, Chief of Staff, Minister's Office | Health Canada (HC)
    • Jean-Yves Duclos, Minister of Health | Health Canada (HC)
    • Jean-Sébastien Bock, Director of Policy, Minister's Office | Health Canada (HC)
    Subject matters:
    • Health
  32. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-05-30
    Posted: 2022-06-08
    Designated public office holders:
    • Eric Costen, Senior Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Simon Kennedy, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Industry
    • Science and Technology
    • Health
  33. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-03-25
    Posted: 2022-03-25
    Designated public office holders:
    • Sandenga Yeba, Conseiller principal, Politiques - bureau de Quebec, Cabinet du ministre | Health Canada (HC)
    Subject matters:
    • Health
  34. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-03-03
    Posted: 2022-04-16
    Designated public office holders:
    • Tom Kmiec, Member of Parliament, Calgary Shephard | House of Commons
    Subject matters:
    • Research and Development
    • Health
  35. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-02-14
    Posted: 2022-02-14
    Designated public office holders:
    • Jean-Sébastien Bock, Directeur des politiques, Santé Canada | Health Canada (HC)
    Subject matters:
    • Health
  36. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-01-27
    Posted: 2022-02-14
    Designated public office holders:
    • Luc Berthold, Député | House of Commons
    Subject matters:
    • Health
  37. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-12-09
    Posted: 2021-12-16
    Designated public office holders:
    • Jean-Yves Duclos, Ministre de la santé, Cabinet du ministre | Health Canada (HC)
    Subject matters:
    • Health
  38. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-12-06
    Posted: 2021-12-16
    Designated public office holders:
    • Luc Berthold, Député | House of Commons
    Subject matters:
    • Health
  39. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-12-01
    Posted: 2021-12-03
    Designated public office holders:
    • Miro Froehlich, Policy Advisor | Health Canada (HC)
    • Jean-Sebastien Bock, Director of Policy | Health Canada (HC)
    Subject matters:
    • Health
  40. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-11-22
    Posted: 2021-12-15
    Designated public office holders:
    • Marc Miller, Minister of Indigenous Services | Indigenous Services Canada (ISC)
    Subject matters:
    • Science and Technology
    • Industry
    • Health
  41. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-11-09
    Posted: 2021-12-15
    Designated public office holders:
    • François-Philippe Champagne, Minister of Innovation Science and Industry, Minister's Office | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Science and Technology
    • Health
    • Industry
  42. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-07-07
    Posted: 2021-08-16
    Designated public office holders:
    • Erin O'Toole, Member of Parliament, Official Leader of the Opposition | House of Commons
    Subject matters:
    • Science and Technology
    • Health
    • Research and Development
    • Industry
  43. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-06-21
    Posted: 2021-07-15
    Designated public office holders:
    • Erin O'Toole, Member of Parliament | House of Commons
    • Pierre Paul-Hus, Member of Parliament | House of Commons
    • Richard Martel, Member of Parliament | House of Commons
    Subject matters:
    • Research and Development
    • Industry
    • Science and Technology
    • Health
  44. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-06-04
    Posted: 2021-07-15
    Designated public office holders:
    • Luc Thériault, Member of Parliament | House of Commons
    Subject matters:
    • Industry
    • Health
    • Science and Technology
  45. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-06-01
    Posted: 2021-07-15
    Designated public office holders:
    • Jordan Matte, Policy Advisor, Office of the Leader of the Opposition | House of Commons
    • Holly Duggan, Stakeholder Relations Advisor, Office of the Leader of the Opposition | House of Commons
    • Alexander MacDonald, Policy Advisor, Office of the Leader of the Opposition | House of Commons
    Subject matters:
    • Science and Technology
    • Industry
    • Health
  46. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-05-20
    Posted: 2021-06-15
    Designated public office holders:
    • Sabina Saini, Chief of Staff, Office of the Minister | Health Canada (HC)
    • Kathryn Nowers, Senior Policy Advisor, Office of the Minister | Health Canada (HC)
    Subject matters:
    • Research and Development
    • Science and Technology
    • Health
  47. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-05-19
    Posted: 2021-06-15
    Designated public office holders:
    • Joey Wong, Special Assistant to Jean Yip, MP | House of Commons
    • Jean Yip, Member of Parliament | House of Commons
    Subject matters:
    • Science and Technology
    • Health
    • Research and Development
  48. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-05-19
    Posted: 2021-06-15
    Designated public office holders:
    • Mike Lake, Member of Parliament | House of Commons
    • Nina Childs, Constituency Manager | House of Commons
    • Jaclyn Preece, Constituency Manager | House of Commons
    Subject matters:
    • Health
    • Science and Technology
    • Research and Development
  49. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-04-30
    Posted: 2021-05-15
    Designated public office holders:
    • Jean Yip, Member of Parliament | House of Commons
    Subject matters:
    • Industry
    • Health
  50. Novartis Pharmaceuticals Canada Inc.
    Type: In-house Corporation
    Occurred: 2021-04-29
    Posted: 2021-05-15
    Designated public office holders:
    • Alexandre Deslongchamps, Director of Operations, Minister's Office | Natural Resources Canada (NRCan)
    Subject matters:
    • Industry
    • Health

Date Modified: